Five years managing metastatic non-small cell lung cancer: Experience at a teaching hospital

Internal Medicine Journal

Volumn 34, Issue 8, 2004, Pages 458-463

  Wong, S ^a   Rosenthal, M A ^a   DeBoer, R ^a   Green, M D ^a   Fox, R M ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Metastatic non small cell lung cancer; Multidisciplinary approach; Referral patterns

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; NAVELBINE;

ADULT; AGED; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; HISTOPATHOLOGY; HOSPITAL MANAGEMENT; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONCOLOGY; PATIENT CARE; PATIENT REFERRAL; PRIORITY JOURNAL; RADIOTHERAPY; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TEACHING HOSPITAL; TREATMENT INDICATION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HOSPITALS, TEACHING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 4444317176     PISSN: 14440903     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2004.00636.x     Document Type: Review

References (21)

1. Giles G. The cancer epidemic in Victoria. Health of Victorians. The Chief Health Officer's Bulletin 2000; 2: 23-6.
2. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-8.
4. Lilenbaum RC, Langenberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced non-small-cell lung carcinoma. A meta-analysis of response, toxicity, and survival. Cancer 1998; 82: 116-26.
5. Wozniak AJ, Crowley JJ, Balcerzal SP, Weiss GR, Spiridonidis H, Baker LH et al. Randomised trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group Study. J Clin Oncol 1998; 16: 2459-65.
6. Kelly K, Crowley JJ, Bunn PA, Presant CA, Grevstad PK, Moinpour CM et al. Randomised phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group Trial. J Clin Oncol 2001; 19: 3210-18.
7. Bonomi P, Kim KM, Fairclough D, Cella D, Kugler J, Rowinsky E et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group Trial. J Clin Oncol 2000; 18: 623-31.
8. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F et al. TAX 320 Non-Small Cell Lung Cancer Study Group. Randomised phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354-62.
9. Richardson GE, Thursfield VJ, Giles GG for the Anti-Cancer Council of Victoria Lung Cancer Study Group. Reported management of lung cancer in Victoria in 1993: comparison with best practice. Med J Aust 2000; 172: 310-11.
10. Schroen AT, Detterbeck FC, Crawford R, Rivera P, Socinski MA. Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. Chest 2000; 118: 129-37.
11. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of literature and future directions. Clin Cancer Res 1998; 4: 1087-100.
12. Giles GG, Whitfield K, Thursfield V. Cancer in Victoria, 1996. Canstat, 28. Melbourne: Melbourne Cancer. Epidemiology Centre, Anti-Cancer Council of Victoria 1999.
13. Hawson G, Zimmerman PV, Ford CA, Johnston NG, Fibrouz-Abadi A. Primary lung cancer: characterization and survival of 1024 patients treated in a single institution. Med J Aust 1990; 152: 230-34.
14. Earle CC, Venditti LN, Neumann PJ, Gelber RD, Weinstein MC, Potosky AL et al. Who gets chemotherapy for metastatic lung cancer? Chest 2000; 117: 1239-46.
15. Raby B, Pater J, Mackillop WJ. Does knowledge guide practice? Another look at the management of non-small cell lung cancer. J Clin Oncol 1995; 13: 1904-11.
16. Gridelli C. The Elderly Lung Cancer Vinorelbine Italian Study Group. A phase III study of single agent vinorelbine as first-line treatment in elderly patients with advanced NSCLC. Oncologist 2001; 6: 4-7.
17. Ramsey SD, Moinpour CM, Lovato LC, Crowley JJ, Grevstad P, Presant CA et al. Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst 2002; 94: 291-7.
18. Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomised trial. J Natl Cancer Inst 2002; 94: 173-81.
19. Gridelli C, Cigolari S, Gallo C, Manzione L, Ianniello GP, Frontini L et al. Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small cell lung cancer elderly patients: Phase II data from the multicenter Italian Lung Cancer in the Elderly Study (MILES) randomised trial. Lung Cancer 2001; 31: 277-84.
20. Jaakkimainen L, Goodwin PJ, Pater J, Warde P, Murray N, Rapp E et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomised trial in non-small cell lung cancer. J Clin Oncol 1990; 8: 1301-9.
21. Le Chevalier T, Brisgand D, Doulliard JY, Pujol JL, Alberola V, Monnier A et al. Randomised trial of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-67.